[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-disease":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,51,77,100,125,154,179,201,229,251,268,297,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":4,"leadSponsor":47,"locationsCount":50},"100143838","characterization-of-patients-with-uncommon-presentations-andor-uncommon-diseases-associated-with-the-cardiovascular-system-100143838",false,"NCT01143454","Characterization of Patients With Uncommon Presentations and\u002For Uncommon Diseases Associated With the Cardiovascular System","Cardiovascular Disease Discovery Protocol","* INCLUSION CRITERIA:\n\nEligible subjects may include anyone over 1 year of age who is affected with diseases\u002Fdisorders (index cases), or who is a relative of a person who is affected with diseases\u002Fdisorders. Relatives may include genetic carriers and non-carriers.\n\n* Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.\n* Index cases enrolled in this protocol will have been referred with a known or suspected pathology that may be associated with cardiovascular dysfunction or risk with a suspected atypical presentation, heritable disorder, or genetic predisposition. The investigator with expertise in the presentation of the subject, along with consulting specialists, will review the medical history and may review any medical records that are available of prospective subjects and offer admission based upon the potential to help the individual, to learn from the subject, or to initiate clinical or basic research suggested by the subject s workup.\n\nEXCLUSION CRITERIA:\n\n* Persons of less than 1 year of age or greater than 100 years of age\n* Healthy volunteers unable to give informed consent or who decline to have blood and\u002For tissue studies, or who do not consent to have samples stored for future research may be excluded from this study.\n* Pregnant women\n* Persons who are not fluent in the English language will be excluded from Patient Reported Outcome Questionnaires. Such persons would be unable to properly complete questionnaires that are only valid in the English language.",true,"ALL","1 Year","100 Years",{"count":21,"type":22},5000,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at a high risk for heart diseases or diseases of their blood vessels. Depending on the condition being studied, both affected and nonaffected individuals may be asked to provide blood and other samples and may undergo tests to evaluate the heart, blood vessels and lung function. The testing is tailored to the individual and\u002For condition being studied. Nonaffected individuals may include relatives of affected individuals and healthy nonrelated volunteers.\n\nObjectives:\n\n\\- To study individuals who have or are at risk for cardiovascular diseases, and in some cases their unaffected relatives and healthy volunteers.\n\nEligibility:\n\n\\- Individuals between 1 and 100 years of age. Participants may be healthy volunteers, individuals with cardiovascular diseases, or unaffected relatives of individuals with cardiovascular diseases.\n\nDesign:\n\n* Participants will have some or all of the following tests, as directed by the study researchers:\n* Photography of the face and full body\n* Body measurements\n* Radiography, including chest or limb x-rays\n* Metabolic stress testing to study heart and muscle function\n* Echocardiography to study heart function\n* Magnetic resonance imaging (MRI) studies, including cardiovascular MRI, angiography, and contrast MRI, to study heart function and performance\n* Computed tomography (CT) angiogram to obtain images of the heart and lungs\n* Positron emission tomography (PET) imaging to study possible fat infiltration of the heart\n* Six-minute walk test to study heart, lung, and muscle function and performance\n* Vascular ultrasound to study blood vessel walls\n* Blood, tissue, and other specimens will be collected for research and testing, and will be taken either as part of the clinical study or during surgical procedures.\n* Follow-up studies may be performed under separate research protocols.",[26,27,28,29,30,31],"Metabolic Disease","Obesity","Li-Fraumeni Syndrome","Cardiomyopathy","Atherosclerosis","Inflammatory Disease",[33,34,35,36,37,38,39],"Cardiac Disease","iPS Cells","Cardiac Risk Factors","Cardiac Disease Discovery","Natural History","Heart Disease","Heart Disease Risk","RECRUITING","2026-06-30",{"date":43,"type":44},"2026-07-01","ACTUAL",{"date":46,"type":44},"2010-07-21",{"name":48,"class":49},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",3,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100537257","68gallium-fapi46-petct-imaging-in-chronic-inflammatory-and-fibrotic-diseases-100537257","NCT06275477","68Gallium-FAPI46 PET\u002FCT Imaging in Chronic Inflammatory and Fibrotic Diseases","PARADISE","Inclusion Criteria:\n\n* Patient aged 18 or over.\n* Affected by one of the pathologies concerned by the study (see Table 4)\n* Satisfying the consensus classification criteria for the pathology (Table 3).\n* Satisfying the corresponding clinical situation (Table 3).\n* Negative urine pregnancy test for women of childbearing age.\n* Affiliated with or benefiting from social security.\n* Informed consent (personally dated and) signed by the participant or any representatives (impartial witness\u002Ftrusted person).\n\nExclusion Criteria:\n\n* Patients unable to consent.\n* Incapacitated adults.\n* Pregnant or breastfeeding women.\n* Patients refusing to participate in research.\n* Known active cancer.\n* Women of childbearing potential unwilling to use appropriate contraception (definitions given in Annex 1).","18 Years",{"count":60,"type":22},390,"INTERVENTIONAL",[63],"NA","This single-center pilot study is designed to explore the preliminary utility of the \\[68Ga\\] Ga-FAPI imaging agent in positron emission tomography (PET) combined with computed tomography (CT) for a range of chronic inflammatory and fibrosing diseases. The study focuses on the potential of \\[68Ga\\] Ga-FAPI, a novel radiotracer targeting Fibroblast Activation Protein (FAP), to improve diagnostic accuracy in various medical conditions. Thirteen distinct clinical situations have been selected for this investigation, including rheumatoid arthritis, liver fibrosis, and systemic lupus, among others. This approach aims to ascertain the value of further clinical development in each area and refine the use of this imaging modality in routine care for both initial evaluation and ongoing monitoring of these diseases.",[31],"2026-06-15",{"date":68,"type":44},"2026-06-16",{"date":70,"type":44},"2025-03-13",{"date":72,"type":22},"2028-10-05",{"name":74,"class":75},"University Hospital, Brest","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":76},"100638948","establishment-of-a-multimodal-standard-database-for-inflammation-related-ophthalmopathy-100638948","NCT07628946","Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy","Inclusion Criteria:\n\n1. Retinal vascular and metabolic-related diseases: Diabetic Retinopathy (DR, including NPDR and PDR), Retinal Vein Occlusion (RVO), Hypertensive Retinopathy.\n2. Degenerative diseases: Age-related Macular Degeneration (including dry and wet forms), Pathologic Myopia (PM), Polypoidal Choroidal Vasculopathy (PCV).\n3. Immune-mediated and inflammatory eye diseases: Uveitis (including primary and secondary), Optic Neuritis, Mooren's Ulcer, and corneal melting associated with systemic immune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n4. Anterior segment and ocular surface syndromes: Various types of Dry Eye Disease (DED), Keratoconus, Glaucoma (especially cases with chronic inflammation or long-term medication use).\n5. Developmental fundus diseases in children and adolescents: Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP).\n6. Patients with a confirmed diagnosis of fundus diseases, including Diabetic Retinopathy, Pathologic Myopia, Age-related Macular Degeneration, Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP), and other adult or pediatric fundus diseases.\n7. Ability to cooperate with study examinations, including acceptance of Ultra-Widefield (UWF) fundus photography, OCT\u002FOCTA, AOSLO, corneal confocal microscopy, meibomian gland function assessment, corneal esthesiometry, and tear film function tests. Image quality must meet analytical standards.\n8. Availability of complete or follow-up accessible ophthalmic medical records.\n9. Blood pressure ≤ 160\u002F100 mmHg (to avoid exacerbating ischemia due to uncontrolled hypertension).\n\nExclusion Criteria:\n\n1. Recent (within the past 3 months) corneal\u002Fconjunctival acute inflammation, ocular surgery, or ocular trauma; or presence of corneal alterations (e.g., contact lens wear).\n2. Fundus images that are uninterpretable or severely obscured (e.g., vitreous hemorrhage).\n3. Use of medications affecting tear secretion (e.g., antihistamines, antidepressants) within the past 30 days.","3 Years",{"count":85,"type":22},3000,"Through a systematic observational study, the intrinsic connections and patterns between the occurrence and development of common blinding retinal diseases such as diabetic retinopathy, pathological myopia, and age-related macular degeneration and the changes in fine parameters of the anterior structure of the eye are deeply explored. To achieve this goal, investigators will adopt cutting-edge multimodal imaging technology to simultaneously collect precise data from ocular surface and fundus of participants. By integrating and analyzing these multi-dimensional information from different parts of the same eye, investigators will build a high-quality and standardized ocular surface-fundus associated image database. This database not only aims to reveal potential ocular surface biomarkers that can be used for early warning or auxiliary diagnosis, but also lays a solid data foundation for the future development of artificial intelligence-assisted diagnostic tools and the establishment of a brand-new ocular surface-fundus integrated diagnosis and treatment assessment model.",[88,31,89,90],"Ocular Surface Disease","Retinal Disease","Choroid Diseases","2026-06-01",{"date":93,"type":44},"2026-06-05",{"date":95,"type":44},"2025-11-26",{"date":97,"type":22},"2030-02",{"name":99,"class":75},"Dan Chen",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":76},"100440187","evaluation-of-high-dose-prednisolone-pharmacokinetics-in-the-acute-and-chronic-setting-100440187","NCT05012033","Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","EHD-Pred PK","Inclusion Criteria:\n\n* Aged 18 - 75 years\n* Male or female\n* Participants who are otherwise healthy enough to participate, as determined by pre-study medical history\n* Participants who are able and willing to give written informed consent to participate in the study\n* Group A only: Patients requiring acute (\\\u003C5 days) high dose (minimum 30mg) oral prednisolone therapy for antiinflammatory purposes in either an inpatient or outpatient setting.\n* Group B only: Minimum of 1 month duration of high dose prednisolone (\\>30mg) if in the chronic use group.\n* Group C only: Patients started on high dose methylprednisolone (\\>3 day course) or prolonged courses of dexamethasone.\n\nExclusion Criteria:\n\n* Participants with a diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Unable to give informed consent.\n* Taking supplements or herbal medications that the participant is unwilling or unable to stop prior to and during the study period e.g. St John's Wort (may decrease prednisolone levels), Cat's claw, Echinacea (immunomodulatory properties).\n* Currently taking medications that alter CYP3A4 metabolism of glucocorticoids that the participant is unwilling or unable to stop prior to and during the study period e.g. phenytoin, phenobarbital, rifampicin, rifabutin, carbamazepine, primidone, aminogluethimide, itraconazole, ketoconazole, ciclosporin or ritonavir.\n* Pregnancy. Females of child-bearing age will be asked to provide a urine sample for a pregnancy test at each visit.\n* History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.","75 Years",{"count":109,"type":22},120,"This is a pilot study to investigate serum prednisolone profiles in:\n\n* Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting.\n* Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone.\n\nThe study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone.\n\nThe study aims to measure prednisolone levels at a number of time points to investigate serum profile differences in those receiving prednisolone acutely compared with longer term steroid use. Further samples will be taken to characterise additional metabolic changes.",[112,113,114,115,31],"Thyroid Eye Disease","Vasculitis","COPD Exacerbation Acute","Asthma","2026-03-24",{"date":118,"type":44},"2026-03-27",{"date":120,"type":44},"2023-04-12",{"date":122,"type":22},"2030-12-31",{"name":124,"class":75},"Imperial College London",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":16,"sex":17,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":76},"100467248","molecular-diagnosis-of-systemic-autoinflammatory-diseases-100467248","NCT05364294","Molecular Diagnosis of Systemic Autoinflammatory Diseases","SAIDiag","Inclusion Criteria:\n\n* A patient presenting with a clinical and biological aseptic inflammatory syndrome associating one or more of the following signs: spontaneously resolving fever, abdominal (pain, diarrhea), locomotor (arthralgia, myalgia), thoracic (pain, pericarditis), cutaneous, sensory (uveitis, deafness), or renal (amyloidosis) involvement.\n\nExclusion Criteria:\n\n* Adult subject to legal protection measures (guardianship, curatorship, safeguard of justice).","1 Week","120 Years",{"count":135,"type":22},300,"Systemic autoinflammatory diseases (SAIDs) are a set of rare clinically and genetically heterogeneous conditions. The project proposes to identify novel genes and specific signatures in subgroups of patients with SAIDs.",[31,138,139,140,141],"Genetic Disease","Somatic Mutation","Molecular Sequence Variation","Molecular Pathway Deregulation",[143],"Biomarkers","2026-03-04",{"date":146,"type":44},"2026-03-05",{"date":148,"type":44},"2022-05-18",{"date":150,"type":22},"2033-05-02",{"name":152,"class":153},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":76},"100154331","the-1200-patients-project-studying-the-implementation-of-clinical-pharmacogenomic-testing-100154331","NCT01280825","The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing","Inclusion Criteria:\n\n* Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial\n* Life expectancy of at least 3 years\n* Must be 18 years or older\n* Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years\n* Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:\n\n  * Patients requiring specialized cardiology care\n  * Patients with inflammatory bowel diseases\n  * Patients with systemic autoimmune or inflammatory diseases\n  * Patients requiring long-term oral anticoagulation\n  * Patients with hepatitis C\n  * Patients with non-metastatic cancer\n\nExclusion Criteria:\n\n* Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.\n* Patients who have undergone, or are being actively considered for, liver or kidney transplantation.\n* Inability to understand and give informed consent to participate.",{"count":161,"type":22},1200,"The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.",[164,165,166,167,31,168,169,170],"Patients Undergoing Routine Health Care","Heart Diseases","Inflammatory Bowel Diseases","Autoimmune Disease","Blood Coagulation Disorders","Hepatitis C","Non-Metastatic Neoplasm","2026-03-02",{"date":144,"type":44},{"date":174,"type":44},"2011-01-14",{"date":176,"type":22},"2027-12-14",{"name":178,"class":75},"University of Chicago",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":76},"100416102","genetic-variants-and-regulation-of-specialized-pro-resolving-mediator-100416102","NCT04698291","Genetic Variants and Regulation of Specialized Pro-resolving Mediator","Identifying the Effect of Genetic Variants on Specialized Pro-resolving Mediators and Their Association With Chronic Inflammatory Conditions","Inclusion Criteria:\n\n* Current volunteer of the Genes \\& Health program with (test) or without (control) relevant genetic mutations. Genes \\& Health is a huge long-term study of 100,000 people of Bangladeshi and Pakistani origin focuses to link genes with health records and to study disease and treatments. When a volunteer participates in this program, they agree to the possibility to be invited for further studies. Gene \\& Health program invites volunteers to take part in two regions of the UK: East London and Bradford.\n\nExclusion Criteria:\n\n1. Volunteer that has not had their genome sequenced after taking part in Stage 1 of Genes \\& Health program.\n2. Volunteer with significant genetically inherited conditions.\n3. Any abnormality or pre-existing disease which, in the opinion of the investigator, might either expose the subject to risk, or influence the validity of the results.\n4. Volunteer that went under surgery and are recovering.\n5. Participation in a clinical study of a new chemical entity, biological product or a prescription medicine, or loss of more than 400 mL blood, within the previous 3 months.\n6. Presence or history of drug or alcohol abuse.",{"count":187,"type":22},200,"Inflammation is the way that the body reacts against infection, injury or illness. An uncontrolled inflammatory response can lead to the development of inflammatory diseases, such as rheumatoid arthritis and cardiovascular conditions. Recent studies have shown that inflammation is a regulated process coordinated by a group of molecules known as specialized pro-resolving mediator (SPM). These molecules are produced by enzymes via the enzymatic conversion of essential fatty acids; whereas their biological actions are mediated by proteins expressed on the surface of cells known as receptors.\n\nGiven the central role that pro-resolving mediators play in regulating the immune response, the aim of this study is to investigate whether there are genetic variants (mutations) in genes encoding for enzymes and receptors involved in the biology of these molecules and to determine how these mutations affect SPM's activity or function.\n\nFindings made as part of these studies will help shed light into mechanism influencing disease onset and\u002For progression and potentially enhance the discovery of new and more effective treatments.",[190,31,191],"Healthy","Cardiovascular Diseases","2026-02-03",{"date":194,"type":44},"2026-02-05",{"date":196,"type":44},"2021-05-06",{"date":198,"type":22},"2027-12-08",{"name":200,"class":75},"Queen Mary University of London",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":208,"targetDuration":209,"studyType":23,"phases":4,"briefSummary":210,"conditions":211,"keywords":218,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":76},"100581061","clinical-features-current-treatment-and-clinical-outcomes-in-patients-with-inr-cad-a-cohort-study-100581061","NCT06845410","Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study","Clinical Features, Current Treatment and Clinical Outcomes in Patients With Inflammation-associated Non-rapidly-progressive Coronary Artery Disease (INR-CAD): a Cohort Study","Inclusion criteria\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Meeting the clinical diagnostic criteria for INR-CAD, including: (1) Angiographic evidence of coronary lesions (≥ 50% diameter stenosis, de novo or restenotic); (2) Evidence of chronic inflammation within 24 months: (A) Positive inflammatory markers (erythrocyte sedimentation rate \\[ESR\\], high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin-6 \\[IL-6\\], tumor necrosis factor-alpha \\[TNF-α\\], et al; at least twice, ≥ 12 weeks apart), or (B) Positive autoantibodies (at least twice, ≥ 12 weeks apart), or (C) Established diagnosis of chronic inflammatory diseases (autoimmune disease, systemic vasculitis, psoriasis, tuberculosis, et al), or (D) Receiving immunosuppressive therapy (glucocorticoids, immunosuppressive agents, et al).\n4. NOT meeting the clinical diagnostic criteria for IR-CAD, including: (1) Hospitalization due to myocardial ischemia, including: (A) Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV), and (B) Non-invasive evidence of myocardial ischemia; (2) Angiographic evidence of new or worsened coronary lesions (de novo or restenotic) considered relevant to myocardial ischemia, which occurred: (A) Within 6 months of last coronary angiography in any patients, or (B) Within 12 months of last coronary angiography in patients receiving immunosuppressive therapy within 24 months.\n5. Received, or are receiving, or will receive the 24-month clinical follow-up defined by the clinical follow-up protocol for INR-CAD.\n\nExclusion Criteria:\n\n1. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n2. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n3. Vital organ failure.\n4. Life expectancy \\\u003C 1 year.\n5. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n6. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n7. Previous enrollment in this study.\n8. Participation in another study within 30 days.\n9. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n10. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":109,"type":22},"24 Months","This is a cohort study to investigate the clinical features, current treatment and clinical outcomes in patients with inflammation-associated non-rapidly-progressive coronary artery disease (INR-CAD).",[212,213,214,215,216,31,217],"Coronary Artery Disease","Coronary Artery Disease Progression","Coronary Artery Stenosis","Coronary Artery Restenosis","Inflammation","Inflammation Vascular",[212,219,216],"Progression, Disease","2025-11-16",{"date":222,"type":44},"2025-11-19",{"date":224,"type":44},"2025-04-01",{"date":226,"type":22},"2026-12",{"name":228,"class":75},"Peking Union Medical College Hospital",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":76},"100516647","disease-characteristics-of-ir-cad-a-case-control-study-100516647","NCT06007248","Disease Characteristics of IR-CAD: a Case-control Study","Disease Characteristics of Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Case-control Study","Inclusion Criteria:\n\nCase group (IR-CAD patients):\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Prior history of coronary revascularization (PCI or coronary artery bypass graft \\[CABG\\]).\n4. Receiving standard treatment for secondary prevention of AS-CAD after the last coronary revascularization.\n5. Hospitalization due to rapidly-progressive myocardial ischemia:\n\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.\n6. Angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.\n7. Evidence of inflammation:\n\n   * At least one of the indexes indicating active inflammation has ever been elevated (ESR, high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin \\[IL\\]-6, tumor necrosis factor \\[TNF\\]-α, ferritin, et al); or\n   * Established diagnosis of systemic autoimmune disease or systemic vasculitis; or\n   * Receiving immunosuppressive therapy.\n\nControl group (AS-CAD patients):\n\n1. ≥ 45 and \\\u003C 65 years of age (based on the age distribution of the patients currently enrolled in the IR-CAD cohort study), male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Currently, 12±6 months after the last PCI.\n4. Receiving standard treatment for secondary prevention of AS-CAD after the last PCI.\n5. Coronary angiography and\u002For optical coherence tomography (OCT) performed during the present hospitalization.\n6. No evidence of rapidly-progressive myocardial ischemia, which is defined as follows:\n\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last PCI.\n7. No angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.\n\nExclusion Criteria:\n\nCase group (IR-CAD patients):\n\n1. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n2. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n3. Active acute or chronic infection (human immunodeficiency virus \\[HIV\\], tuberculosis, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. Contraindications for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, glucocorticoids, immunosuppressive agents.\n8. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n9. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n10. Previous enrollment in this study.\n11. Participation in another study within 30 days.\n12. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n13. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.\n\nControl group (AS-CAD patients):\n\nThe same as those for the case group (IR-CAD patients).","45 Years","64 Years",{"count":239,"type":22},30,"The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD and 10 patients with AS-CAD.",[212,214,215,213,216,31,217],[212,243,219,216,244],"Coronary Revascularization","Characteristics Disease",{"date":222,"type":44},{"date":247,"type":44},"2023-11-02",{"date":249,"type":22},"2026-09",{"name":228,"class":75},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":258,"targetDuration":209,"studyType":23,"phases":4,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":267,"locationsCount":76},"100505364","efficacy-and-safety-of-comprehensive-treatment-in-patients-with-ir-cad-a-self-controlled-cohort-study-100505364","NCT05860400","Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study","Efficacy and Safety of Comprehensive Treatment in Patients With Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Self-controlled Cohort Study","Inclusion Criteria:\n\n1. Fulfilling all the following criteria before initiation of comprehensive treatment:\n\n   1.1 18 years of age or older, male or female.\n\n   1.2 Negative result of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n\n   1.3 Prior history of coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass graft \\[CABG\\]).\n\n   1.4 Receiving standard treatment for secondary prevention of atherosclerotic coronary artery disease (AS-CAD) after the last coronary revascularization.\n\n   1.5 Hospitalization due to rapidly-progressive myocardial ischemia:\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.\n\n   1.6 Angiographic evidence of new coronary lesions (de novo stenoses or restenoses):\n   * Occurred after the last coronary revascularization; and\n   * Related to myocardial ischemia (location, extent, severity, et al).\n\n   1.7 Evidence of inflammation:\n   * At least one of the markers indicating active inflammation has ever been elevated (erythrocyte sedimentation rate \\[ESR\\], high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin \\[IL\\]-6, tumor necrosis factor \\[TNF\\]-α, ferritin, et al); or\n   * Established diagnosis of systemic autoimmune disease or systemic vasculitis; or\n   * Receiving immunosuppressive therapy.\n2. Receiving comprehensive treatment, including ischemia-driven PCI which was performed no earlier than 40 days of the initiation of immunosuppressive therapy.\n\nExclusion Criteria:\n\n1. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n2. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n3. Active acute or chronic infection (human immunodeficiency virus \\[HIV\\], tuberculosis, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. Contraindications for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, glucocorticoids, immunosuppressive agents.\n8. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n9. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n10. Previous enrollment in this study.\n11. Participation in another study within 30 days.\n12. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n13. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":259,"type":22},39,"This is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the same group of patients.",[212,214,215,213,216,31,217],[212,243,219,216],{"date":222,"type":44},{"date":265,"type":44},"2023-05-17",{"date":249,"type":22},{"name":228,"class":75},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":279,"conditions":280,"keywords":285,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":76},"100492823","7-tesla-mri-brain-imaging-to-decipher-filgotinibs-mode-of-analgesic-action-in-rheumatoid-arthritis-100492823","NCT05697159","7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis","Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis","TEMPO","Inclusion Criteria:\n\nPatients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are:\n\n* Adults ≥18 years \\\u003C 75 years.\n* Right-handed (to reduce neuroimaging heterogeneity).\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.\n* Severe physical impairment (e.g. blindness, deafness, paraplegia).\n* Pregnant or breast feeding.\n* Severe claustrophobia precluding MRI.\n* Contraindications to MRI.\n* Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury.\n* Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.","74 Years",{"count":278,"type":22},20,"This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients.\n\nThe investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate.\n\nThe second is related to peripheral inflammation, specifically joint synovitis, blood cytokines\u002Fchemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.",[281,282,31,283,284],"Rheumatoid Arthritis","Sickness Behavior","Autoimmune","Pain, Chronic",[286,287],"Chronic pain","Rhuematoid arthritis","2025-01-13",{"date":290,"type":44},"2025-01-14",{"date":292,"type":44},"2023-08-22",{"date":294,"type":22},"2025-10-31",{"name":296,"class":75},"NHS Greater Glasgow and Clyde",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":61,"phases":308,"briefSummary":310,"conditions":311,"keywords":314,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":76},"100520701","phase-3-induction-treatment-with-subcutaneous-infliximab-for-crohns-disease-100520701","NCT06059989","InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","A Multicenter Randomized, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn's Disease","DIRECTCD","Inclusion Criteria:\n\n1. Patients 18 years or older diagnosed with Crohn's disease\n2. Patients with moderate to severely active Crohn's disease with a Crohn's Disease Activity Index (CDAI) of 250 to 450 and presence of endoscopic ulceration in the terminal ileum, colon or both. Minimal SES-CD is ≥ 6 or ≥ 4 for isolated ileal disease.\n3. Patients who had no response or loss of response to or have had intolerable side effects to one or more to the following: glucocorticoids, thiopurines (azathioprine\u002F6-mercaptopurine\u002F6-thioguanin), methotrexate , adalimumab, vedolizumab or ustekinumab OR patients in need of immediate top-down treatment with IFX at the discretion of the treating physician.\n4. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements.\n5. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedure.\n6. Male or non-pregnant, non-lactating females. No wish to become pregnant in the coming 26 weeks.\n\nExclusion Criteria:\n\n1. Patients at imminent need of surgery as judged by the treating clinician\n2. Patients with the short bowel syndrome, an ostomy or a symptomatic non-inflammatory stricture\n3. Patients previously exposed to IFX (intravenous or subcutaneous)\n4. Previously unacceptable side effects or intolerance to all immunosuppressants (both thiopurines and methotrexate)\n5. Treatment with adalimumab or vedolizumab or ustekinumab within 30 days\n6. Patients who have had a primary non-response to adalimumab or had intolerable class-related side effects (as evaluated at the discretion of the treating physician)\n7. Enteric pathogens (such as Salmonella, Shigella, Yersinia, Campylobacter and C. difficile) detected by stool analysis within 2 weeks prior to enrollment or at screening\n8. Ongoing participation in another interventional trial\n9. Patients with Ulcerative Colitis or Inflammatory bowel disease unclassified (IBD-U)\n10. Patients with ongoing abdominal or undrained perianal abscess\n11. Patients with a history of colon cancer or colonic dysplasia, unless sporadic adenoma, which has been removed\n12. Active or latent tuberculosis (screening according to national guidelines). Except when the latter has been treated appropriately according to national guidelines.\n13. Cardiac failure in the New York heart Association (NYHA) stage III-IV\n14. History of demyelinating disease\n15. Recent live vaccination (≤ 4 weeks)\n16. Patients with ongoing acute\u002Fchronic infection (including but not limited to HIV, hepatitis B and C) with the exception of chronic herpes labialis or cervical human papillomavirus (HPV)\n17. History of cancer in the last 5 years with the exception of non-melanoma skin cancer\n18. Male patients with Epstein-Barr virus (EBV) negative serology\n19. A history of alcohol or illicit drug use that in the opinion of the principal investigator (PI) would interfere with study procedures\n20. Patients with psychiatric problems that in the opinion of the PI would interfere with study procedures\n21. Patients unable to attend all study visits\n22. Patients with a history of non-compliance with clinical study protocols\n23. Contraindication for endoscopy\n24. Patients who received any investigational drug in the past 30 days or 5 half-lives, whichever is longer\n25. Pregnancy or lactation or wish to become pregnant in the coming 26 weeks","80 Years",{"count":307,"type":22},158,[309],"PHASE3","Study Design:\n\nA Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous (SC) Infliximab (IFX) with and without Immunomodulators during Induction treatment in Moderate to Severe Crohn's Disease.\n\nPrimary endpoint:\n\nThe proportion of patients in corticosteroid-free clinical remission (as defined by a Crohn's disease activity index (CDAI)\\\u003C150) and endoscopic response (as defined by a simple endoscopic score for Crohn's disease (SES-CD) drop of at least 50%) at week 26.\n\nAccrual and feasibility:\n\nThis study will enroll 158 subjects at approximately 20 sites in the Netherlands (peripheral and academic hospitals). The estimated enrollment is 0.5 patient\u002Fcentre\u002Fmonth leading to an inclusion duration of 16 months once all centres are open. The first enrolment is anticipated in Q1 2021.\n\nTreatment, dosage and administration:\n\nEligible patients will be randomized to receive SC IFX monotherapy (240mg at week 0 and week 2 and then 120mg every other week (EOW) OR SC IFX (240mg at week 0 and week 2 and then 120mg EOW) in combination with immunosuppression.",[31,312,313],"Disease Crohn","Bowel Disease",[315,316,317],"Crohn's disease","Biological","Subcutaneous","2024-12-05",{"date":320,"type":44},"2024-12-10",{"date":322,"type":44},"2021-11-25",{"date":324,"type":22},"2025-12",{"name":326,"class":75},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":336,"conditions":337,"keywords":343,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":50},"100554367","active-pharmacovigilance-study-of-the-medicine-rinvoq-upadacitinib-100554367","NCT06498167","Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)","LOOK-UP","Inclusion Criteria:\n\n* Prescription of Rinvoq™ from January 1, 2024;\n* 18 years of age or older at the time of recruitment; and\n* Expressed consent to participate in the study.\n\nExclusion Criteria:\n\n* They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;\n* They are participating in a phase I, II, or III clinical trial;\n* They have a life expectancy of less than 1 month; or\n* They do not have a valid telephone contact.",{"count":335,"type":22},150,"The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \\& Co. KG.",[31,338,339,340,341,342],"Drug Side Effect","Drug Use","Adverse Drug Event","Adverse Drug Reaction","Safety Issues",[344,345,346,347,348,349,350,315,351,352,353],"Upadacitinib","Rinvoq","Rheumatoid arthritis","Psoriatic arthritis","Axial spondyloarthritis","Atopic dermatitis","Ulcerative colitis","Pharmacovigilance risk","Drug safety monitoring","Patient Safety","2024-07-12",{"date":356,"type":44},"2024-07-15",{"date":358,"type":44},"2024-07-01",{"date":360,"type":22},"2024-12-31",{"name":362,"class":75},"Universidade do Porto"]